58972-21-7

Usage

Uses

Used in Flavoring Agents:
Methyl 5-benzoylfuran-2-carboxylate is used as a flavoring agent in the food industry, where its aromatic properties contribute to enhancing the taste and aroma of various food products.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, Methyl 5-benzoylfuran-2-carboxylate is utilized as a key intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Synthesis:
Methyl 5-benzoylfuran-2-carboxylate is also employed in the synthesis of agrochemicals, where it serves as a building block for the creation of new compounds with agricultural applications, such as pesticides or herbicides.
Used in Organic Compounds Synthesis:
Methyl 5-benzoylfuran-2-carboxylate is further used in the synthesis of other organic compounds, expanding its applications across various chemical and industrial sectors. Its versatility in chemical reactions makes it a valuable component in the development of novel organic molecules with diverse uses.

InChI:InChI=1/C13H10O4/c1-16-13(15)11-8-7-10(17-11)12(14)9-5-3-2-4-6-9/h2-8H,1H3

Upstream product

• 611-13-2 2-furoic acid methyl ester 
• 98-07-7 Benzotrichlorid 
• 98-88-4 benzoyl chloride 
• 67-56-1 methanol 
• 2689-59-0 (furan-2-yl)(phenyl)methanone 
• 67-66-3 chloroform 
• 2527-98-2 methyl 5-bromo-2-furoate 
• 611-73-4 Benzoylformic acid 
• 93-97-0 benzoic acid anhydride 
• 2527-99-3 methyl 5-bromo-2-furoate 
• 201230-82-2 carbon monoxide 
• 98-80-6 phenylboronic acid 

Downstream Products

• 170632-18-5 5-methoxycarbonylfuryl phenyl ketone benzylhydrazone 
• 58972-30-8 5-(1-phenyl-1H-indazol-3-yl)-furan-2-carboxylic acid methyl ester 
• 170632-47-0 1-benzyl-3-(5-hydroxymethyl-2-furyl)indazole 
• 170632-13-0 1-benzyl-3-(5-methoxycarbonyl-furan-2-yl)-1H-indazole 
• 377739-88-3 5-methoxycarbonylfuryl phenyl ketone benzylhydrazone 
• 35897-51-9 5-benzoyl-furan-2-carboxylic acid 
• 1917-16-4 5-benzyl-furan-2-carboxylic acid 

Relevant academic research and scientific papers

N-(4-acetamidophenyl)-5-acetylfuran-2-carboxamide as a novel orally available diuretic that targets urea transporters with improved PD and PK properties

Urea transporters (UTs) have been identified as new targets for diuretics. Functional deletion of UTs led to urea-selective urinary concentrating defects with relative salt sparing. In our previous study, a UT inhibitor with a diarylamide scaffold, which is denoted as 11a, was demonstrated as the first orally available UT inhibitor. However, the oral bioavailability of 11a was only 4.38%, which obstructed its clinical application. In this work, by replacing the nitro group of 11a with an acetyl group, 25a was obtained. Compared with 11a, 25a showed a 10 times stronger inhibitory effect on UT-B (0.14 μM vs. 1.41 μM in rats, and 0.48 μM vs. 5.82 μM in mice) and a much higher inhibition rate on UT-A1. Moreover, the metabolic stability both in vitro and in vivo and the drug-like properties (permeability and solubility) of 25a were obviously improved compared with those of 11a. Moreover, the bioavailability of 25a was 15.18%, which was 3 times higher than that of 11a, thereby resulting in significant enhancement of the diuretic activities in rats and mice. 25a showed excellent potential for development as a promising clinical diuretic candidate for targeting UTs to treat diseases that require long-term usage of diuretics, such as hyponatremia.

Direct Alkoxycarbonylation of Heteroarenes via Cu-Mediated Trichloromethylation and in Situ Alcoholysis

We report an efficient approach for direct alkoxycarbonylation of furans as well as other heteroarenes via a one-step copper-mediated reaction of three components (i.e., heteroarene, alcohol, and CHCl3). The copper additive was confirmed to simultaneously promote the reaction in three pathways: oxidant cracking, single electron transfer, and alcoholysis. By means of this protocol, various functionalized furancarboxylates and other heteroarenecarboxylates were facilely obtained in moderate to good yields.

FIVE-MEMBERED HETEROCYCLIC DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention relates to a five-membered heterocyclic compound having an analgesic effect and a pharmaceutical composition comprising a derivative of the five-membered heterocyclic compound. More specifically, the present invention relates to a me

Room-Temperature Decarboxylative Couplings of α-Oxocarboxylates with Aryl Halides by Merging Photoredox with Palladium Catalysis

Enabled by merging iridium photoredox catalysis and palladium catalysis, α-oxocarboxylate salts can be decarboxylatively coupled with aryl halides to generate aromatic ketones and amides at room temperature. DFT calculations suggest that this reaction proceeds through a Pd0-PdII-PdIII pathway, in which the PdIII intermediate is responsible for reoxidizing IrII to complete the IrIII-IrIII-IrII photoredox cycle. Like a mergin': Enabled by merging iridium photoredox catalysis and palladium catalysis, palladium-catalyzed decarboxylative coupling of α-oxocarboxylates with aryl halides can proceed at room temperature. DFT calculations suggest that a Pd0-PdII-PdIII catalytic cycle is merged with an IrIII-IrIII-IrII photoredox cycle, in which PdIII is responsible for oxidizing IrII to complete the photoredox cycle.

EP2 RECEPTOR AGONISTS

A compound of formula (III): or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20alkyl group; L′ is a single bond, —O— or —C(═O)—; A is selected from the group consisting of: formulae (i) (ii) (iii) wherein X and Y are selected from the group consisting of: O and CR3; S and CR3; NH and CR3; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; D is selected from: formulae (i) (ii) (iii) (iv) (v) (vii) (viii) (ix) B is selected from the group consisting of: formulae (A) (B) where RP6 is selected from fluoro and chloro; and R2 is either: (i) —CO2H; (ii) —CONH2; (iii) —CH2—OH; or (iv) tetrazol-5-yl.

Preferential inhibition of release of pro-inflammatory cytokines

A method for preferentially inhibiting release of pro-inflammatory cytokines over release of anti-inflammatory cytokines using a fused pyrazolyl compound of formula (I): A is R or in which R is H, alkyl, aryl, cyclyl, heteroaryl, or heterocyclyl; each of

Novel fused pyrazolyl compound

A fused pyrazolyl compound of the following formula: wherein A, Ar1, Ar2, R1, R2, R3, and R4, are as defined herein. Also disclosed is a pharmaceutical composition containing an effective a

1-Benzyl-3-(5′-hydroxymethyl-2′-furyl)-indazole (YC-1) derivatives as novel inhibitors against sodium nitroprusside-induced apoptosis

Antiapoptotic agents based on 1-benzyl-3-(5′-hydroxymethyl-2′-furyl)indazole (22, YC-1) derivatives were explored for effective treatment of sepsis and septic shock. We found that compound 22, 1-benzyl-3-(5′-methoxymethyl-2′-furyl)indazole (27), and 1-phe

Method of treating disorders related to protease-activated receptors-induced cell activation

A method of treating a disorder related to cell activation induced by protease-activated receptors. The method includes administering to a subject in need thereof a compound having a pyrazolyl core; an aryl group, via an via an alkylene linker, bonded to 1-N of the pyrazolyl core; a second aryl group fused at 4-C and 5-C of the pyrazolyl core; and a third aryl group bonded directly to 3-C of the pyrazolyl core.

Synthesis of 1-benzyl-3-(5′-hydroxymethyl-2′-furyl)indazole analogues as novel antiplatelet agents

1-Benzyl-3-(5′-hydroxymethyl-2′-furyl)indazole (28, YC-1) was selected as the lead compound for systemic structural modification. After screening for antiplatelet activity, SARs of YC-1 analogues were established. Among these potent active derivatives, co